57 results found

To date, the applications of cell therapies have largely fallen into two broad categories; tissue regeneration and immuno-modulation.

The recent decision by the European Patent Office (EPO)'s Technical Board of Appeal 3.3.04 in T 96/20 appears, at first glance, to have raised the bar for acknowledging the inventive step of medical use...

In this article for Intellectual Property Magazine, Mathys & Squire partner Juliet Redhouse and technical assistant Angela Stephen examine the different strategies for lengthening patent coverage at the European Patent Office (EPO).

In this article, we have provided an overview of six Mathys & Squire clients in the clean-tech and sustainability space, whose ground-breaking innovations are helping to combat climate change.

Have you created a strategy to address how you will enforce and fund the protection of your intellectual property (IP) assets, if required?...

European patents can be opposed by ‘any person' within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin.

Following the order issued on 16 July 2021, the Enlarged Board of Appeal (EBA) has now published its full written Decision in G 1/21.

As reported previously in Business Weekly, Guangzhou Xiangxue Pharmaceuticals (Xiangxue) recently became the first Traditional Chinese Medicine (TCM) company to establish a base in the UK, at the Babraham Research Campus near Cambridge.

The Petition for Review procedure at the European Patent Office (EPO) is a limited form of judicial review enabling parties to have the Enlarged Board of Appeal review decisions made by an EPO Board of Appeal and vacate such decisions if it is established that a fundamental procedural error has occurred.

In support of its economic growth, China has been busy putting into place an IP system comparable to those in the West, and which address protection of trade marks, patents, copyright and trade secrets.

Any business that develops new products or processes runs the risk of infringing third party patent rights, which can result in the business being drawn into patent disputes.

Trading Technologies’ patent dispute has brought the issue of protecting intellectual rights to the fore like never before. Paul Cozens looks at the risks behind not taking the right precautions.

Further to our article in July 2020 on the EPO Enlarged Board of Appeal's hearing in G1/19, the Enlarged Board has now published its long-awaited decision relating to the patentability...

Often the IP due diligence aspect of a transaction is an afterthought, considered to be a complex and tedious formality, and left to the eleventh hour.

An aspect of European intellectual property (IP) law that is widely underappreciated is the powerful protection now available for features of design of an enormously wide variety of products.